Tampere, Finland – Vactech Oy (Vactech), a biotechnology company focused on development of vaccines for Type 1 Diabetes and other immune mediated diseases, today announced that the United States Patent and Trademark Office has issued US Patent 7,972,592 B2 covering prevention of Type 1 Diabetes Mellitus and other non-polio enterovirus diseases by eliminating the risk effect of enterovirus infections.

This application is a divisional application filed on Mar. 12, 2002, now US patent 7,090,855 B1.

Field of the invention

The invention relates to the prevention of Type 1 diabetes and other non-polio enterovirus diseases by a novel vaccination regime based on extensive immunisations by currently available oral poliovirus vaccine (OPV) and/or by new non-polio enterovirus vaccines. The invention provides prevention of Type 1 Diabetes Mellitus and other non-polio enterovirus diseases by eliminating the risk effect of enterovirus infections.

"After more than 10 years of correspondence with the US Patent office examiner Vactech finally was granted this patent which completes the IPR protection on the preventive Type 1 Diabetes vaccine and offers us exclusive rights in the USA", said Raimo Harju, CEO of Vactech.

About Vactech

Vactech develops and licenses vaccines and novel technologies for vaccines and diagnostics with a pipeline of early stage product candidates focused on Type 1 Diabetes, Celiac Disease, Asthma & Allergy and diagnostics.

Vactech’s flagship project is a patented enterovirus based preventive Type 1 Diabetes (T1D) vaccine, similar to the widely used enterovirus vaccine against polio. The vaccine is a traditional inactivated vaccine and it has been proved to be safe and effective in mice. In addition, Vactech’s IMAVAC™ product line uses Virus Like Particle (VLP) technology which is essential for other vaccines, immunomodulators and diagnostic applications.

Vactech is a privately owned company. We have a track record of collaboration with big pharma on the level of Good Laboratory Practice (GLP). We consider ourselves as an attractive investment target for those that believe in and want to grow with our mission.

For more information contact:

Please see the company's website at www.vactech.fi for additional information or contact:

Raimo Harju, CEO

• Prev
• Next